Emmessar Biotech And Nutrition (BOM:524768) Notes Receivable: ₹0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524768 Emmessar Biotech And Nutrition Ltd BOM:524768
55 GF Score
Price ₹25.34
GF Value ₹18.67
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Emmessar Biotech And Nutrition Notes Receivable?

Emmessar Biotech And Nutrition BOM:524768 +1.93% 55 Notes Receivable is ₹0.00 Mil as of Mar. 2026. GuruFocus rates BOM:524768 with a GF Score™ of 55/100 and a GF Value™ of ₹18.67 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Emmessar Biotech And Nutrition's Notes Receivable for the quarter that ended in Mar. 2026 was ₹0.00 Mil.

Emmessar Biotech And Nutrition Notes Receivable Related Terms

Emmessar Biotech And Nutrition Notes Receivable Historical Data

* Premium members only.

The historical data trend for Emmessar Biotech And Nutrition's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emmessar Biotech And Nutrition Notes Receivable Chart

Emmessar Biotech And Nutrition Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Emmessar Biotech And Nutrition Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:524768
55GF Score
Emmessar Biotech And Nutrition Ltd BOM:524768
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Emmessar Biotech And Nutrition Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ₹0.00 Mil mean?
Emmessar Biotech And Nutrition (BOM:524768) has a Notes Receivable of ₹0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Emmessar Biotech And Nutrition and its competitors.
Is Emmessar Biotech And Nutrition's Notes Receivable too high?
Emmessar Biotech And Nutrition's current Notes Receivable is ₹0.00 Mil. Overall, Emmessar Biotech And Nutrition has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emmessar Biotech And Nutrition's Notes Receivable compare to ZTS?
Emmessar Biotech And Nutrition's Notes Receivable of ₹0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Emmessar Biotech And Nutrition and its competitors. Emmessar Biotech And Nutrition's current Notes Receivable is ₹0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmessar Biotech And Nutrition stock overvalued right now?
Based on GuruFocus' analysis, Emmessar Biotech And Nutrition (BOM:524768) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹18.67, compared to a current price of ₹25.34 — trading 35.7% above its estimated fair value. The current Notes Receivable is ₹0.00 Mil. Emmessar Biotech And Nutrition's overall GF Score™ is 55/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Emmessar Biotech And Nutrition (BOM:524768), the current Notes Receivable is ₹0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Emmessar Biotech And Nutrition (BOM:524768) Overvalued in 2026?

Based on GuruFocus' analysis, Emmessar Biotech And Nutrition stock appears to be overvalued. The current stock price of ₹25.34 is trading 35.7% above its estimated GF Value™ of ₹18.67. GuruFocus considers Emmessar Biotech And Nutrition to be Significantly Overvalued.

Key valuation signals for BOM:524768:

  • Notes Receivable: ₹0.00 Mil
  • GF Value™: ₹18.67 vs. price of ₹25.34 (35.7% above fair value)
  • GF Score™: 55/100 with 1 warning sign

No single metric tells the full story. See the BOM:524768 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Emmessar Biotech And Nutrition Business Description

Address 38, Cawasji Patel Street, 29, Kamer Building, 4th floor, Fort, Mumbai, MH, IND, 400001
Emmessar Biotech And Nutrition Ltd is a healthcare company. The company is engaged in the manufacturing and marketing of fine chemicals products, and healthcare and nutritional products. The company caters to patients with obstinate skin problems, muscle problems, bone problems, and other debilitating chronic physical ailments. The business segments of the company are Healthcare, Fine Chemicals, and Rent on Immovable property of which the majority of the revenue is derived from the Rent on Lease land segment.
55GF Score

Get the complete analysis for BOM:524768

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹25.34
Price
₹18.67
GF Value